Trial · NCT00429949
Results by group33
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 33
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Response Rate [Complete Response (CR) and Partial Response (PR)] | Dasatinib 70 mg BID | Complete response | 0 | 0.5 to 17.3 | participants |
| Response Rate [Complete Response (CR) and Partial Response (PR)] | Dasatinib 100 mg BID | Complete response | 0 | participants | |
| Response Rate [Complete Response (CR) and Partial Response (PR)] | Dasatinib 70 mg BID | Partial response | 0 | participants | |
| Response Rate [Complete Response (CR) and Partial Response (PR)] | Dasatinib 100 mg BID | Partial response | 1 | participants | |
| Time to Response | Dasatinib | 5 | cycles | ||
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III anemia | 5 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III neutropenia | 2 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III thrombocytopenia | 2 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade IV thrombocytopenia | 3 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III epistaxis | 2 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III gastrointestinal bleed | 1 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III acute renal failure | 2 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III headache | 1 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III aphasia due to laryngeal plasmacytoma | 1 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III neuropathy | 1 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III fatigue | 1 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III hypertension | 1 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III diarrhea | 1 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III leg/hip pain | 1 | participants | |
| Safety and Tolerability of Dasatinib (Grade III-IV Toxicities) | Dasatinib | Grade III generalized pain | 3 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00429949/results